Results 1 to 10 of about 84,367,963 (213)

Electroanalytical Overview: The Sensing of Mesalamine (5-Aminosalicylic Acid) [PDF]

open access: yesACS Measurement Science Au, 2023
Mesalamine, known as 5-aminosalicylic acid, is a medication used primarily in the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.
Robert D. Crapnell   +2 more
doaj   +3 more sources

Prospective Questionnaire Survey on Adherence to Oral 5‐Aminosalicylic Acid in Patients With Ulcerative Colitis [PDF]

open access: yesJGH Open
Background Adherence to 5‐aminosalicylic acid (5‐ASA), an anchor drug for ulcerative colitis (UC), affects remission maintenance. This study aimed to investigate the current status of adherence to 5‐ASA and identify the factors associated with adherence.
Tsuyoshi Beppu   +9 more
doaj   +2 more sources

Perimyocarditis in a Patient with Ulcerative Colitis Treated with 5-Aminosalicylic Acid [PDF]

open access: yesThe Korean Journal of Gastroenterology
5-Aminosalicylic acid (5-ASA) is recommended for managing ulcerative colitis. Common adverse effects associated with 5-ASA include gastrointestinal disorders, headaches, and skin rashes.
Hye Young Lee, Dong Hoon Baek
doaj   +2 more sources

5-Aminosalicylic Acid Distribution into the Intestinal Membrane Along the Gastrointestinal Tract After Oral Administration in Rats [PDF]

open access: yesPharmaceutics
Background: 5-Aminosalicylic acid (5-ASA), the first-line therapy for ulcerative colitis, is a poorly soluble zwitterionic drug. Unformulated 5-ASA is thought to be extensively absorbed in the small intestine.
Yorinobu Maeda   +7 more
doaj   +2 more sources

Association of Proton Pump Inhibitor and Potassium‐Competitive Acid Blocker Use With Discontinuation and Intolerance of Oral 5‐Aminosalicylic Acid in Patients With Ulcerative Colitis [PDF]

open access: yesJGH Open
Aims Proton pump inhibitors (PPIs) and potassium‐competitive acid blockers (PCABs) are widely used for acid‐related disorders. Recent studies have raised concerns that acid suppression may alter gut microbiota and drug pharmacokinetics, potentially ...
Shinsuke Otagiri   +4 more
doaj   +2 more sources

Chronopharmacological effects of 5-aminosalicylic acid in the treatment of experimental colitis in mice [PDF]

open access: yesFrontiers in Immunology
Background5-Aminosalicylic acid (5-ASA) is a first-line therapy for ulcerative colitis, but whether dosing timing influences its therapeutic efficacy remains unclear.
Yulin Wen   +5 more
doaj   +2 more sources

5-aminosalicylic acid suppresses osteoarthritis through the OSCAR-PPARγ axis [PDF]

open access: yesNature Communications
Osteoarthritis (OA) is a progressive and irreversible degenerative joint disease that is characterized by cartilage destruction, osteophyte formation, subchondral bone remodeling, and synovitis.
Jihee Kim   +14 more
doaj   +2 more sources

Ultrasonographic features of 5-aminosalicylic acid intolerance in pediatric ulcerative colitis [PDF]

open access: yesClinical and Experimental Pediatrics
Hirotoki Murashige   +3 more
doaj   +2 more sources

5-Aminosalicylic Acid-induced Myocarditis in a Patient with Atypical Ulcerative Colitis

open access: yesThe Korean Journal of Gastroenterology, 2022
5-aminosalicylic acid (5-ASA) is used widely to treat ulcerative colitis. The common side effects of 5-ASA include nausea, vomiting, abdominal pain, headache, and skin rash.
Hyo Yeop Song, Geom Seog Seo
doaj   +1 more source

Effect of Reaction Time and Stability Properties of Gold Nanoparticles Synthesized by p-Aminobenzoic Acid and p-Aminosalicylic Acid

open access: yesIndonesian Journal of Chemistry, 2020
In this work, we determined the influenced of the reaction time at the synthesis of gold nanoparticles (AuNPs) by p-aminosalicylic acid and p-aminobenzoic acid as reducing agent.
Abdul Aji   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy